6
Aug
2025
CAR-T Cells Against Solid Tumors: Sabah Oney on The Long Run
Sabah Oney is today’s guest on The Long Run. Sabah is the CEO of Philadelphia and San Francisco-based Dispatch Biotherapeutics. This startup is developing engineered CAR-T cell therapies for solid tumors. The goal is to bring the power of CAR-T cell cures to a wider group of patients, beyond those with blood cancers. Dispatch was founded by some of the... Read More
